MRSN - Earnings call transcript Q1 2022 | Mersana Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to Mersana Therapeutics First Quarter 2022 Conference Call and webcast. Currently all participants are in a listen-only mode. There will be a question answer session at the end of this call. I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please proceed.

Jason Fredette

everyone. morning, Good

to, actual Each I'd to contain materially on begin, are federal with mention our clinical our and in February Form in not that laws. discussed documents business releases, and annual statements the if Before forward-looking is company's subsequent XX-K SEC platform uncertainties strategy, statements like within those Executive the filings. to will the as potential, limited risks are but and forward-looking report available statements that, to on or preclinical Exchange and the no such filed risks related and law, statements commercial the the or These call call to These these company's we trial study include, to data those meaning statements. securities at sec.gov execution on Chief differ opportunities of Mersana's objectives, SEC that results obligation could XX, and Securities assume projected are Anna in available forward-looking website, becomes in over XXXX, Protopapas, cause the even required uncertainties or Except plans President we from future. regulatory and to cash runway. These mersana.com. subject me Commission information turn and update publicly Officer. let by With of new

Anna Protopapas

conference quarter everyone, morning, Good XXXX call. welcome first our to and

to joined Officer, other questions. Yang, Officer, Lowinger; of Financial today by Chief me and Joining prepared Technology also be who our will members DeSchuytner. Officer, remarks with Tim certain I'm available management Brian our Medical answer are Science and Chief Arvin Chief

of Corporate officially would Senior I Mersana Relations like Communications, and start, Investor to new welcome Fredette. I Before to our Jason VP

is to partnering on the data new advance we continue strategy are bring up position excited Mersana an on to prepared in year exciting imported execute we our for UpRi, clinic have exciting XXXX. candidates shaping be into to incredibly as multiple board. XXXX to to him We two as readouts

we of describing on cancer. by shared patients with advantages, important UpRi's neutropenia, neuropathy as start clinical goal other with made and been has have a the namely our the has past the me and the believe demonstrated UpRi we've Let reported data We progress tolerability lap of ADCs. efficacy in foundational medicine toxicity ovarian for ocular establishing that severe

registration expeditious slate range a while current UPLIFT, profile across complete trial trials, and the is in to us the data ovarian cancer also platinum-resistant of track for quarter have filing. potential of manner. single-arm XXXX Our this on BLA UPLIFT, broad and to UP-NEXT positioning further third validate and generating capital-efficient cancer, in an ovarian UPGRADE, readout our of a potential settings enrollment year, this in

UpRi dose ovarian selection recurrent UP-NEXT even selected patient we need. are high significant an SGO, share at with trial further Phase in detail, supporting discuss oral will NaPiXb population Arvin to III additional is have our Oncology, for larger an monotherapy As or Society of the platinum-sensitive cancer, is maintenance unmet presentation which in our for to been pleased UPLIFT. of analysis Gynecological

into safety into earlier therapy. escalation a our monotherapy. followed late UpRi for of with continuation valuable patients. plans space. trial combination the in by UpRi Phase of setting, the planned and has position lines ADC line combination could as the year Initially, and the will confirmatory global support to our evaluating insights Next registration dose the UpRi's provide of the in We which a in umbrella combination in to I/II tolerability UpRi we're preliminary support carboplatin, this post-approval potential U.S., trial platinum-sensitive first UPGRADE service believe data earlier An expand platinum-sensitive is

XXXX and in is need our a pipeline with XMT-XXXX high compelling at will expressing the endometrial candidates XXXX first and XXXX's I. pipeline range year we including tumors, cell UpRi, validated focus. mid-XXXX. a primary potential of have broadly lung ovarian indications including are to is expressed targets cancer. HERX, in are clinic. on efficacy to Preclinically, unmet non-small Phase generated gastric Dolasynthen cancer. tumors ADC of in a Both a to Beyond directed our of of solid into to and primary STING-agonist breast, These advancing BX-HX clinic track and data, demonstrating manner the move XMT-XXXX be second addition being into move as ADC we focus our and thoughtful expected these It breast, be BX-HX. the capital-efficient this our target clinical we Immunosynthen

pipeline generated agent have a a XXXX's potential and create in single low with expressing product in models. to demonstrating a robust We preclinical activity HERX both a set, high data

in in Given like that and with standard of synergistic breast that newer in to be agents, HERX, other those we the targets potential it care HERX. XXXX have become novel agents epitope cancer believe has including of HERX

Additionally, we in work combination models. checkpoint inhibitors preclinical potential in have its with seen to

XMT-XXXX, cancer. NaPiXb-targeted of short-term many as as evaluating have also we Now goal you in second ADC, a non-small been know, another cell lung

to opportunities prevalence the biomarker UpRi competitive XMT-XXXX the of we XMT-XXXX, in see nature lower we the lung, increasingly to development our financially XMT-XXXX. and indication, of NaPiXb discontinue have disciplined Given the and ahead remain commitment decided this of substantial for

of deferring XXXX, pipeline. clinical certain including pipeline, earlier are our our on investments XMT-XXXX focus in to we two Mersana's our candidates, preclinical stage resources addition, and In

of provides year. this expand can be interest and choice the ability nondilutive when there at its us to as field. our in surge to by in engine our to and partner patient has with the our own a is enabled Dolaflexin, time while reach Mersana's ADC We active of fuel position pipeline in to to positioned in also opportunity of needs us success candidates capital turn, address the This, bringing redeployed and as business. UpRi, XMT-XXXX the that three Dolasynthen view product development and platforms efficient Immunosynthen Mersana Our have platforms, all capital three XXXX clinical this

a and in UpRi off we XXXX for in and the the to a and important hope not-to-distant partnerships. we are potential strong future, for of data start foundation we lay what approval XXXX as BLA initial XXXX additional so clinical will be And value-creating filing

by waiting We who to and opportunities are value for new that the patients treatment Arvin data options. UpRi our to we for SGO. call recent are building steadfastly ahead that, lie into would on remain and turn discuss over at the focused to excited like delve deeper With I

Arvin Yang

from GOG support strong With networks premier oncology Anna. the the you, clinical in the and ENGOT, EU. gynecologic both U.S. and trial Thank

for a SGO, to were remain bifurcated groups, submission patients meaningful to XXXX. this and development third by XX UpRi's UpRi data appropriate progress UPLIFT dose group advancing UPLIFT at we continue the treatment that XX on ovarian in the BLA of complete and we dose enrollment of in disease. report positive, If At make track We data details will across analysis an XX. pleased cancer trial year quarter square in this reaffirmed landscape. to I We believe support dose. the This meter present dose from per analysis group Phase platinum-resistant our mg in

in status to are nonevaluable in high in four XX, helped only population. and two The patients To treatment higher X of among the in dose as fewer fewer well ITT patients overall rate the fewer treatment-related all and Intent Both including XX% group clarify ORR efficacy, of nonevaluable an above Including Treat also ORR with scan. well was were NaPiXb standard XX% discontinuations population overall patients analysis figures adverse NaPXb that with adverse events SGO were first the today's adverse of seen among Grade care. patients. and high before the these high ORR longer of response events, discontinuation general, the dose these or presentation events, XX, group to or durations patients or XX% its as Given in

trial. expect Now turning UP-NEXT that we trial as to serve III will confirmatory Phase our

as are cancer excited remains new Through who position ovarian by three the inhibitors Despite populations to PARP important its today's We underserved medical and previously unmet platinum interactions, to treated are UpRi a the of high patient we've have need care. standard approval opportunity bevacizumab, UP-NEXT who enroll of options. maintenance for FDA been and patients CHP designed with doublet. constructive a by

on or are in patients a progress combination bevacizumab, inhibitor and The sequence. taken whether PARP in who first

by patients and maintenance studies agents achieved disease excluded who are excluded resorting as wait who platinum stable the their and the treatment poorly watch today's labels. median PARP are best are to patients who are PARP Second are the third and inhibitor served are on from in And option. consequently from

And. unmet study and the address a optimized maintenance square setting, have design XX meter the high selecting mg patients for in need NaPiXb including to per We selecting dose the

screening patient boards of review We to for to putting the share us by on we protocol trial institutional pleased to UP-NEXT QX. submitted track initiate are our or IRBs, this end that site

combination for near-term combination In plans and of fourth be from we focus planning the UPLIFT initiate initial share with year. enrollment addition UP-NEXT, are therapy to in interim trial combination primary and of over Tim. To be efforts, UpRi let me this our are XMT-XXXX key to quarter bring to Phase safety data the the I/II with carboplatinum in into our tolerability And further, up now these the into of lines and believe of all earlier combination clinic. UPGRADE turn parallel will we complete ovarian to treatment. to this will we Ultimately, these in discuss XMT-XXXX finally, candidates moving cancer gearing the to call readout.

Tim Lowinger

Thank you, Arvin.

As in the ADC made and medicines. at an is progress you very potential core pipeline we cancer Mersana's building strategy, have out significant innovation of know, of innovative

additional an clinical In compelling, XXXX. and inception excited both demonstrate that validated fact, receptor the are that packages due XMT-XXXX, antitumor precise targeting these ratio payload opportunity triple-negative effect next we drug-to-antibody cancer. BX-HX a tolerability have robust perspective. effect. our Further, a AACR. correlated the never models technology controlled honestly XMT-XXXX both to in are I've Mersana's as of breast to about our Also, new and of since rapid similar our with At them say bystander dose similar and and multiple target company, I Dolasynthen data X. been preclinical to XXXX single provide has UpRi's from has here of This microtubular and will our with is inhibitor in patient-derived data on what desired progress both on to molecules BX-HX, a data and we that optimized antitumor a where be very is ADC leverages we and a estrogen target breast we promise it UpRi, believe activity the xenograft cancer consistent share at showed ADC clinically AACR, been to I DolaLock activity expression and pipeline recently can of candidate, The positive had profile. more both

we presented XXXX data first AACR as As model. and XMT-XXXX our monotherapy antitumor both activity a Immunosynthen HERX-expressing shows robust targeting mentioned, that tumors. at in expressing preclinical is ADC Anna HERX STING-agonist The high low demonstrates

with provide Immunosynthen of differentiation also position data may demonstrating road we efficacy HERX. trastuzumab, trastuzumab combine or We presented shared anti-PD-X other targeting even and and established pertuzumab, like agents deruxtecan. its how on The XXXX clear molecules mechanistic data unique from a provide map greater

great us with myeloid pathway financials. research Additionally, both of to in tumor-resident immune differentiator on agonists This on To toll-like we at cell the and strong activation Ex involve a this to recap activity antigens how cells or a those excitement further elucidating setting our death. now an or ADC-IO samples punch to tumor investigate Translational targeted midyear. TLR dependent tumor approach, we XXXX a in strong target like a STING-agonist STING in AACR preclinical present of those the cells deal pass antitumor cells. activate Brian approaches, conducted Immunosynthen for one-two manner. studies and begin directly based cells other ADCs combined call in induce and the that XXXX presented XXXX the I'd tumor antigen with data revealing rationale investigating STING clinical in like when Immunosynthen to and binding over of provides cancer pathway including that immune is on the this Brian? versus receptor patient vivo,

Brian DeSchuytner

first so quarter this financial just focus me let Thank We few key summarized you, results on Tim. release, a items. morning's press our in in

strength approval in investments demonstrate certain continue proactive that we evaluate been As expenses and same prolonged of related to deferment operating the all now Mersana, potential decisions the caused us market has Immunosynthen we've of to to clinically a platforms. challenging our and XMT-XXXX to the majority like more a know, like At UpRi of the This has contributing and conditions been one for Mersana has Anna situated ensuring XMT-XXXX. carefully, you similarly of advancing described amid in time. capital toward XMT-XXXX access period our even require the to time, rapidly and that to earlier biotechnology company, Dolasynthen

the Net $XXX April, we debt we in who option. activities have raised have use primary at Mersana recent million our opportunity for strategic to XXXX, in Mersana's who with sound cash draw ended our long-term additional the QX line down are credit of to equivalents. million us of investors and Our low-cost million prospects of from our accomplishments $XX with in capital noted SVB Also, be enabled first ATM, operating from the and $XX cash have approximately believe in a We net refinancing business examples keep should proceeds and additional quarter us with strongly financial tend ATM footing. used focus. Oxford an late in $X XXXX the provides in million. of whom with relationships that and had development on tools to an cash long-term primarily was It in that

we As believe continue that XXXX. commitments filing. of reminder, quarter-to-quarter we the Factoring in, of required in have fluctuations plan our as the anticipated we a related financing expect to work our to R&D fund all CMC there approach second BLA to we spending be this half into well operating will

as signed for believe come. that tool within further potential financing the to Additionally, collaborations Janssen arsenal in quarters development exists we transactions to and The important the an that business of was differentiated us continue raise enable to platforms prime now agreement in a I'll validation platforms. view our the while capital turn back quarter can our Anna. to was expanding meaningful and nondilutive of With how call our example the that, reach the first

Anna Protopapas

bolstered of focus company execute With shareholders. ADC the commitment a have to positioned leading the with we're platforms building benefit, Thank our a sheet will we I we believe With and and you, Q&A. to our the over call both that, made Brian. pipeline, balance progress well for upon and turn on a patients operator across

Operator

SVB ahead. question First Chang] with Instructions] Leerink. [Operator Please comes [Jonathan from go

Jonathan Chang

the question, First any delays on enrollment Is any the Have and/or on can related the how in you study? geopolitical COVID you has UPLIFT study track? provide color experienced progressed?

Tim Lowinger

Thanks, Jonathan. great It's to you. hear from

making We're said we on track. on relationship we remain the what we good in timing. and progress So target about to main QX

Jonathan Chang

and the and you there Can expand high-level specific just from on regarding to program to pipeline And UpRi? of experience learned And the through your second are question. lessons that thoughts prioritization resources? read XXXX, that

Anna Protopapas

So for thank you, question. Jonathan, the

of we potential not UpRi decision role as Our around of The XXXX. of cancer, factors. competitive and XXXX really that cohort, lung from but our we're indication the excited involved this fact just of expansion lung the a very nature about XMT-XXXX pretty learned number cancer and NaPiXb the UpRi

indications. XXXX portfolio, gives of very diversified on Focusing XXXX and terms us UpRi platforms both targets, and a in

to from are So do, and that really one one there take -- drove from program study learnings we every are our decision. next. the study there learnings we Obviously, with

with the clean we'll disclose So we an down opportunity the database, as lock wind forum and appropriate there data. to and And to were XXXX. the obviously that find study have learnings

Jonathan Chang

about just you're And discuss for development question moving business me. guys last how additional forward? you Can . opportunities thinking

Brian DeSchuytner

Maybe I Yes. that. take can

ADC part the recognized So we transaction, I here partners both an our we their one about really innovation think, of these. as think ADCs that the be sitting products. have in prime need talked positioned of to ourselves and of highlights have the Janssen platforms number through they I armamentarium. Tim for And companies with A can what renaissance. do our We're that

modality, a that there's can take the six there an immune about Immunosynthen -- three Immunosynthen as -- transaction. that's spot, stimulation are And interested our in similar where a for our sweet platforms to or think assets to the are in that on another stages, in Dolaflexin is into being where those company about the every substrate whether most We of so has think obviously, own. that that various Dolasynthen, platform all partnering clinic advanced cytotoxic platforms, look as advanced. their XXXX transactions The and Janssen we And well. the it's we that the can't strategy pillars: company we've targeted we for BD ADCs

potential the quickly resources be we combination want don't partner reluctant and the of really inflection value UpRi. the advance with to upside. UpRi the partners We in we're Where would the more to we be with first-in-class, here sort in those around stand interesting. points a a class is registration-enabling And only to where close fully owned cap very asset So to next would around study.

Operator

Boris comes from with ahead. Cowen. Please Peaker Your next question go

Boris Peaker

I the approving believe trial well the timing to from regulatory FDA underway sure and make is, is question the accelerated that to perspective, confirmatory first prior My wants application.

curious, do anticipate be of BLA enrolled submitting So far time based your on UP-NEXT I'm how to UPLIFT? you you'd the just when around be

Arvin Yang

Yes. question. No, for the thanks

And to so our as release, QX the in relationship press first we've enrollment. be we remain ongoing track discussing in the in with the we enrollment, FDA regards we've In the off, that off, front referenced. the would as of on just in study been initiation to well start-up to typical as relationship in start as indicated to relationship discussions, in

with addresses other the not competing population in interest -- available, advantageous in unmet an to landscape relationship from confirmatory data the this UPLIFT the in of cancer study. is that the regulators has a keep mind, points some relationship trial study. and already are remember, in a us the obviously, relationship ovarian to when becomes our platinum-resistant differentiates the One those that the in UPLIFT, This obviously thing is standpoint still competitive different And been however, of been doing relative we're to the to designs. confirmatory in population serves space. confirmatory study, ovarian study to need So discussed have the with this

Boris Peaker

question Can XXXX second year? of for provide my later and sets year, seeing the on of in middle some data should we expectation And be the is you what XXXX. this

Anna Protopapas

guided track we clinic dosing patients are midyear. on in and have the So to be

for us that As a for disclosures data providing I to beyond be think early little it's guidance. that,

Operator

Fye Please Your with go JPMorgan. next question from comes Jessica ahead.

Daniel Wolle

This is including A trial, can expression UPGRADE, those of couple rationale all low you with NaPiXb? for Daniel in Maybe comers with, provide Jessica start to including questions. the the for Fye. of regarding

Arvin Yang

Yes. No, thanks question. for the

seen in We in that NaPiXb. across cohort. enrichment And is there from relationship mind -- to the activity expansion see starting board, in that in keep the we've that but the first so there's to relationship the off, data do high

And so in chemotherapy the and with -- mind, steps the with or the neuropathies nonoverlapping we've we're combine the don't as neutropenias, toxicities the initial with what UPGRADE, here to agent, keep again, to the potential that starting and our toxicities. differentiated are we UpRi in recognizing that peripheral evaluate, ocular severe for seen have profile

idea So biomarker here care in see selection. in like which in is standard here then NaPiXb on combination with ultimately, or a whether to a of would relationship the we'd in earlier status patient the be that broad population carboplatin, obviously, line, to the activity and useful not is determine,

Daniel Wolle

OPTIMIST regarding Do ensuring on the you've FDA And it front? FDA, focused dose the recently from you announced the will the then dose. right far project agency on seems satisfy this done think the so is that advance work companies the

Arvin Yang

Yes.

the for question. you thank So

that core is the the we're I on and here. not have quite OPTIMIST tenements for project -- multiple project been OPTIMIST can we've I that that the relationship ranging, that you move the And dose that relationship be selection analyze believe the able evaluated remember, which data almost consistent think patients the dose robustly one to really to been necessarily focused maximum of evaluating our of optimal to see forward been XXX to in is And in dose here, bringing with tolerated patients. have our think always dose it's optimal selection dose, regimen we doses can over forward. is in

Daniel Wolle

take of XXXX program? second account of One last the guidance the into discontinuation runway well question. into of Does the cash XXXX, the half

Brian DeSchuytner

Yes, it does.

Operator

Your next Baird. Colleen Kusy question comes with from

open. is line Your

Colleen Kusy

would for UP-NEXT have you're trial, are us remind of the follow-up. then for enrollment? the arm the a depend for on you So the I in to the breakdown in it stratifying expectations that of And the the what percent can population? enroll? three placebo And you populations different And looking

Arvin Yang

in break And or in So the this space down the and for remind little me platinum-sensitive let audience bit are relationship high recurrent study just to NaPiXb a to the we confirmatory first. UP-NEXT the selecting question patients. study, is

have stratifiers order multiple regards the at in those different stratification, in in so those to then to all the populations, to we size, the populations observation your care that of essentially actually speaks patients. standard acceptable most determined placebo care sample ensure standard And where we've second or the to time these prognostic are upon point, but in the of for question what that care based be. would to of vigilant essentially, as an Because looking balance. that to period And relationship standard relationship important patients as your about

period And space, so utilization that short is line PARP given the in the that, relatively bad that progression-free keep utilization to space, in recurrent actually and inhibitor survival. relationship mind the earlier in

We sharing it's been associated short. that. imagine you recurrent actual relatively space, time But that the haven't can with the in frames

Colleen Kusy

what in time you'll XQ? of effective UPGRADE you're dose for the by an the do And And you trial, the think readout be dose escalation at using? is regimen the

Arvin Yang

Yes.

going seen this. efficacy. meter dose with We're we're we defined are through consistent start I evaluate approved the we where, have down dose keep regimen. carboplatinum setting studies to low dose as the dose, milligrams per obviously, goal escalating using the an initially as safety with to UpRi with So and And UpRi and then it's as here approved mind escalation the starting at in activity dose the in and the a ensure of carboplatinum is then tolerability squared Phase we're of doses XX the that

period. our get to the time into that upon be expectations initial QX, level so this dose in will escalation interim the or And frame, set you as of

the so the and is key safety the in carboplatinum. here tolerability with evaluate And combination to

Colleen Kusy

can. I one, last one if And

earlier ovarian, Just you about do might level, how of platinum thinking you're exposure NaPiXb, of impact if into moving higher on have expression data all? a at UpRi the at lines while

Arvin Yang

It's Yes. great a question.

the we've cohorts, intervening only not level expression seen that through banks, to from as as including therapies. appears the expansion setting expectations space. platinum lineage NaPiXb or that be NaPiXb consistently that And what two-thirds described our would be including marker. time, through late it but is we tumor therapies, thus, the would the represents the dose means consistent the expression remain which so but an is line of which cohorts line of setting, sensitive population be cohort whether And in as about a expansion high, our in additional And in the also well earlier expansion platinum

Operator

Our Please comes Wedbush question go ahead. David Nierengarten with next Securities. from

David Nierengarten

I mine crowded agents HERX-targeting of been but asked, other HERX mechanism, know Immunosynthen. development space. XXXX in developing curious it's is HERX its but differentiated Most have I a was also on from

a that I -- your might So business one that thinking development, you business be that, I be wondering development development at but looking to pathway? of pipeline if you were and opportunities was relatively is expensive if don't say that interesting to might were . just want prime targeting what

Arvin Yang

when Sure. partnerships we be platform Immunosynthen around to remarked potential partnerships the we or as there both Immunosynthen Janssen, our I there platform, assets, before, access think similar the are around mean about products. the could

of index. existing important, David, the we're But antibody The think that is it and we're a component is And agents. is is really a about HERX station, with not here third generated data with this, novel which we've using competitive third-party then interrupt one, we're I molecule, really objective to docking HERX signaling. therapeutic that I been right? have the using HERX-directed demonstrating a binding in really Tim think team not For because, tremendous a -- that excited preclinical

that means today. than that potential be the so are of universe broader much this may of HERX And agents applications where studied

as of so Phase pieces those I things escalation. would that And explore we are dose part of that all

David Nierengarten

to see in I we thinking or the maybe from there on then, And you Phase and follow-up might wait indications competitive have if are about a could any less I? maybe sneak focusing be

Arvin Yang

can I tumor to our that mean just in I speak to relationship types escalation. the dose in

you HERX types. know, variety just indicated, of tumor as you As a is in expressed,

is we'll gastric types, the the evaluating such, relative just really point, would additional that types And of pathway in And bladder three so cancer, a the because docking been Brian's may keeping as and now may evaluating. express non-small HERX. in I this including well to expression cell. to But less the we therapies breast be primary inhibiting also include levels cancers HERX-targeted has to that station. mean, action. be And relationship I tumor the of other right that matter flag back biologic other mind modality where will tumor as

success I a it prime think the address can in relationship a probably in using to population. the best potentially is you in docking example HERX -- the low HERX HERX-low when station, as

into the And hypotheses so these are going clinic. we're some of the that we'll as pursue

Anna Protopapas

this product product. There that be the Dave, clinic really that in really would we saw add, if that a you what many different so potential have we could are can appropriately is a And identified pipeline a realize in I opportunities preclinically.

the well the be future. through could move but along very We the value a proof-of-concept it escalation way build into in it for it now, So be could be early it we good dose can studies. partnering, and as might candidate

Operator

is Kaveri And our with proceed. last question from Please Pohlman BTIG.

Kaveri Pohlman

Regarding believe the those the square Will enrollment with And meter the UPLIFT trial included be dose also study. is second was mg cohort. UPLIFT the XX patients patient started the population? trial, ITT regarding my I question per in in

the to pneumonitis adverse the talk have mitigate events. implemented protocol about you If could you

Arvin Yang

shifted upon And with XXX be then we we forth, dose mg start with based regimen. what the patients optimal first just started the per question. to to dose we squared move me to evaluation regimen had And meter square, to the a had forward. clarify, Let initially the consider and XX so per meter XX mg

the population. used the cohort as So XX be will efficacy dose

be obviously, Now in data the utilized will of order safety the always profile. to characterize totality

I context you will how just different and be So wanted to give data with two the the utilized. in relationships doses

management the about gears to the so you and had question pneumonitis shifting algorithms Now forth.

essentially, standpoint of inclusion the the you learnings criteria less I in that that in such our are had then or really cohorts minimizes that to or up the first, relationship starts expansion were potential of, actually if runway. develop a, from reserve standpoint from set frequencies per think to identifying. it of ability with pulmonary ensuring a the itself the quite from patients way have the to, we've standard algorithm it the is they pneumonitis, se the overcome rare But management have

we're the So in with potential was are a days, But who and pneumonitis. comfortable risk. physicians early probably quite educating the less knowledgeable that this aware

ultimately, whether reductions, that that answered then dose I and as delays, management, as hope identification discontinuations or such additional question. your well be So steroids. interventions as dose through

Operator

with end Anna call Protopapas our pass And the I will ladies final gentlemen, for that, to and remarks. her Q&A. we back

Anna Protopapas

Thank for of forward up date for our and conference starting We on weeks continued to ahead. look you thank to progress in circuit your listening. the see the hopefully you person everyone, more to keeping you, you Until then, in on support.

Operator

Thank gentlemen, and you, today's ladies for program. in participating

great Everyone, You now may have a day. disconnect.

Mersana Therapeutics (MRSN) 9 May 222022 Q1 Earnings call transcript